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INTRODUCTION 
Rectal cancer is among the most frequent cancers in the world.  
There is considerable geographical variation. The incidence is high in 
western countries [1,3]. High intake of fat and calories, use of alcohol and 
tobacco is associated with increased risk.  High intake of diet rich in fiber is 
associated with decreased risk [1].  
Hereditary disorders such as HNPCC associated with 1-3% of all rectal 
carcinoma. FAP associated with <1% of all rectal carcinoma [1].  
Incidence in males is more common than females. Incidence is rising 
steadily after the age of 50.Morethan 90% of cases diagnosed are in people 
older than 50 years of age. However individuals at any age can develop [1]. 
Prognosis for rectal carcinoma has improved since the 1960s, and this is 
probably due to early diagnosis, better preoperative tumor staging, improved 
intra-operative care, improved surgical technique and improved adjuvant 
treatments such as radiation and chemotherapy.  
Incidence of local recurrence and distant metastasis also has decreased 
because of the above said reasons. But still the management of local recurrence 
is difficult.  
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AIM OF THE STUDY 
1. To determine the predominant age and sex presenting with carcinoma 
rectum.  
2. To study the incidence of various clinical manifestations of carcinoma 
rectum.  
3. To find out the incidence of site of involvement of carcinoma rectum  
4. To study the incidence of various stages of carcinoma rectum at 
presentation.  
5. To evaluate the role of neo adjuvant chemo radiation.  
6. To evaluate the surgical modalities of carcinoma rectum.  
7. To find out the incidence of morbidity and mortality following surgical 
management of carcinoma rectum.   
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ANATOMY  
 Rectum  
           Begins at the level of sacral promontory.  
Follows  the curve of sacrum and ends at anorectal junction.  
Is 12-15 cms in length. 
Has 3 lateral curvatures  - Upper and lower are convex to the   
    right                        
     Middle is convex to the left.  
On luminal aspect, 3 curvatures are marked by Houstan’s Valve.  
Rectum divided into   
 Upper 1/3 rd  - has peritoneal covering.  
 Middle 1/3rd – peritoneum covers anterior and part of the lateral 
surfaces.  
 Lower 1/3rd lies deep in the pelvis surrounded by fatty 
mesorectum.  
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ANATOMICAL LOCATION OF RECTUM  
 
 
CORONAL SECTION OF RECTUM 
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ARTERIAL SUPPLY OF RECTUM 
 
 
VENOUS DRAINAGE OF RECTUM 
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Lower 1/3rd of rectum separated by:  
           Denovillier’s fascia from prostate in males and vagina in females,  
          Waldeyer’s fascia from the coccyx and lower 2 sacral vertebra[2]. 
Arterial supply  
Upper 1/3 rd  - superior rectal artery – branch from inferior mesenteric artery  
Middle 1/3rd - middle rectal artery – branch of internal iliac artery  
Lower 1/3rd – inferior rectal artery – branch of internal pudendal artery [1]. 
Venous drainage  
 Superior rectal vein – drains into portal system through inferior mesenteric 
vein.  
Middle rectal vein – drains into caval system through internal iliac vein.  
Inferior rectal vein – drains into caval system through internal pudendal vein [1].  
Lymphatic drainage  
 Parallel to the vascular supply.  
Upper and middle rectum – drains into inferior mesenteric lymph nodes  
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LYMPHATIC DRAINAGE OF RECTUM 
 
NERVE SUPPLY OF RECTUM 
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Lower rectum – drains superiorly into inferior mesenteric nodes laterally into 
internal iliac nodes[1].  
Nerve supply  
 Sympathetic fibers – from L1-L3 – forms hypo gastric plexus at sacral 
promontary which subsequently joins parasympathetic fibers to form pelvic 
plexus at the lateral wall of rectum.  
 Parasympathetic fibers – nervi erigentes – from S2-S4 join sympathetic 
fibers to form pelvic plexus at the lateral wall of  rectum [1].  
 
 
 
 
 
 
 
14 
 
PATHOPHYSIOLOGY 
 Normally colonic mucosa regenerates approximately every 6 days. Cells 
migrates from base of crypts to the surface where  it undergoes differentiation, 
maturation and degeneration.  
I. Adenoma may precede into adenocarcinoma by adenoma to carcinoma 
sequence [1,3].  
II. APC Adenoma carcinoma pathway  
 Mutation in APC gene 
 
Unchecked cellular replication at crypt surface  
    
Further mutation leads to K-ras oncogene mutation in early stage and                         
P53 mutation in later stage 
 
Prevents apoptosis and prolong the cells life span indefinitely.  
III. Mutation in DNA mismatch repair genes found in 90% of HNPCC, and   
      15% of sporadic rectal cancers [8].  
IV. Ulcerative colitis dysplasia 
Chronic inflammation  Genetic alterations  dysplasia   
carcinoma[3].  
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EPIDEMIOLOGY  
 Incidence of colorectal cancers tends to be higher in western than in 
Asian and Africans.   
 Approximate incidence per 1,00,000 people 
 Africa   - 2 
 Asia    - 15 
South America - 15 
West Europe  - 40 
USA   - 35 
 Although the incidence of colon and rectal cancer varies considerably by 
country, an estimated 944,717 cases identified worldwide in 2000[4].  
Sex  
 Incidence in males is slightly higher than in female.  
 In males  -  65/100000 
 In females  -  47/100000     
The male female ratio is 1.37% [4]. 
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Age 
 Incidence of colorectal cancer starts to increase after the age of 35 and 
rises rapidly after the age of 50, peaking in seventh decade. This shows that 
prolonged exposure to weak environmental carcinogens is necessary to induce 
tumors and that most, possibly all, pass through the benign phase before turning 
into malignant [4].  
ETIOLOGY  
Multifactorial in origin including environmental, genetic factors.75% of 
cases are sporadic and 15-20% of cases are associated with family history, 
personal history of colorectal cancers/ polyps. 
Other risk factors - HNPCC - 1-3%  
   FAP – 1% 
   IBD – 1%  [1]. 
Environmental factors  
Diet  
 High fat diet and low fiber diet increases the risk of developing 
colorectal carcinoma. Fiber diet forms soft bulky stools which dilute the 
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carcinogens and decreases the colonic transit time, thereby allowing less time 
for carcinogens to contact with mucosa. Increased dietary intake of calcium 
binds with fatty acids and bile acids which lead to antiproliferative effects on 
crypt epithelial cells [22].  
 Selenium, carotenoids, vitamin C and D have protective effects by 
scavenging free oxygen radicals in the colon [1].  
Alcohol  
   More than 30gms of alcohol intake per day is associated with increased 
risk of developing rectal carcinoma [23].  
Smoking 
  Smoking is associated with increased risk of developing rectal carcinoma 
especially when started at a young age, due to production of toxic polycyclic 
aromatic amine and induction of angiogenic mechanisms [24].  
Post cholecystectomy  
 After cholecystectomy, free flow of bile into the colon occurs which is 
acted upon by bacteria and produces carcinogenic bile acid byproducts [1,3].  
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Hereditary factors  
 The relative risk of developing colorectal cancer is increased in the first 
degree relatives of the affected patients. For off-spring, the relative risk is 2.42. 
If more than one family member affected, the relative risk increases to 4.25.If 
the first degree family member is younger than 45 years at the time of 
diagnosis, the risk increase is even higher [29].     
GENETIC FACTORS  
Familial Adenomatosus Polyposis (FAP) 
 It is a autosomal dominant condition due to mutation in the APC gene 
located in chromosome 5q21, which results in the development of more than 
100 adenomatous polyps. FAP is associated with osteomas of bone, desmoid 
tumors and brain tumors. If left untreated, carcinoma develops in nearly 100% 
of patients by the age of 40. 
HNPCC 
     It is autosomal dominant condition due to mutation in mismatch repair 
genes located on chromosomes 2, 3 and 7. HNPCC have same number of 
polyps as general population. But they are more prone to develop malignancy. 
HNPCC associated with endometrial, thyroid, gastric and brain tumor.  
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COLONOSCOPIC VIEW OF FAMILIAL ADENOMATOSUS POLYPOSIS  
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Revised Amsterdam criteria  
   It is used to select at risk patients. 
 Criteria are  
- 3 or more relatives who are diagnosed with an HNPCC 
associated cancer.  
- One affected person is a first degree relative of the other 2.  
- One or more cases are diagnosed before 50 years of age.  
- At least 2 generations are affected.  
- FAP has been excluded [11].  
INFLAMMATORY BOWEL DISEASE 
 Chronic inflammation in IBD produces dysplastic changes which in turn 
increases risk of developing colorectal carcinoma. After 10 years of duration in 
patients with IBD, the incidence of colorectal cancer is 4-20 times greater than 
the general population.  
IRRADIATION  
Intracavitary irradiation in the treatment of carcinoma cervix is 
associated with increased risk of developing rectal carcinoma. It usually 
appears 5 to 15 years later.  
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HISTORY AND CLINICAL FEATURES 
A complete history including family history and assessment of other risk 
factors are mandatory. Carcinoma rectum patients may be asymptomatic and 
discovered during DRE/ proctoscopic examination.  
COMMON SYMPTOMS  
Bleeding  
Bleeding is the most common symptom, present in 60% of patients. 
Usually profuse bleeding and anemia are rare.  
Change in bowel habits  
Change in bowel habits is present in 43% of patients. Diarrhoea occurs 
particularly if the tumor has large villous component and in patients with 
growth in the ampulla of rectum. Constipation is common in annular lesion at 
pelvic rectal junction. Tumors in the lower 1/3rd of the rectum cause incomplete 
evacuation and tenesmus. 
Occult bleeding  
 Occult bleeding present in 26% of cases which is detected by FOBT.  
 
22 
 
Abdominal pain  
Abdominal pain present in 20% of cases.  
 Usually present in advanced growth in recto-sigmoid junction 
Uncommon symptoms and signs  
 Back Pain is present when carcinoma invades / compresses sacral plexus 
present in 5% of cases.  
Urinary symptoms - If invading / compressing the bladder / Prostate.  
Bowel obstruction - In 9% of cases 
Malaise - In 9% of cases.  
Perforation -  In 3% of cases  
Jaundice - In liver metastasis patients - <1%. 
Rectovaginal fistula  
Supra clavicular lymph node enlargement  
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PATHOLOGY, STAGING AND PROGNOSIS 
MACROSCOPIC APPEARNACE: 
Macroscopically cancer rectum may be 
1. Proliferative  
2. Ulcerative 
3. Annular 
4. Diffusely infiltrating 
5. Colloid 
1. The proliferative type is the most frequently occurring one. It forms a 
fleshy bulky polypoid mass that bulges into the lumen of the bowel. It is 
a malignant adenoma of slow growth and of low order of malignancy 
and arises from the wall of the gut and forms a wide base. The 
proliferative growths are usually well differentiated adenocarcinoma. 
2. Ulcerative growth present as a typical malignant lesion with raised 
irregular everted edges and a sloughing floor. It has tendency to infiltrate 
the bowel wall. 
 
24 
 
 
 
 
 
CUT SECTION OF ANNULAR GROWTH AT RECTO SIGMOID 
JUNCTION 
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3. The annular type of growth is seen typically in the upper 1/3 of the 
rectum. Small densely hard slow growing tumor that do not project into 
the rectum apparently but tends to encircle the gut wall and thus 
obstructing the passage of solid fecal matter. 
4. Diffusely infiltrating carcinoma colon & rectum produces a diffuse 
thickening of the intestinal wall usually extending at least 5 to 8 mm and 
for the most part covered with mucosa but there is usually ulceration at 
some point. This form of carcinoma is sometimes found as an extension 
of one of the other gross type of the growth. It is also the infrequently the 
type of carcinoma that develops in ulcerative colitis. 
5. Colloid carcinoma usually forms a bulky growth with very suggestive of 
gelatinous appearance. There may not be extensive ulceration and 
infiltration. 
HISTOPATHOLOGICAL GRADING AND TYPING: 
Grading depends upon subjective interpretation of the degree of 
differentiation at histological examination. Various grading systems have been 
proposed, but grading into two broad groups, low or average grade tumors 
which are well to moderately differentiated and high grade or undifferentiated 
induces the variation between observers while at the same time providing useful 
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prognostic information. Patients with high grade cancers have worse prognosis 
when compared with patients with well differentiated lesions after taking 
account of the tumor stage. 
Typing on the other hand reflects the cellular characteristics. Mucinous, 
signet cell and small cell tumor are the variants of the more common 
adenocarcinoma .Signet cell and small cell tumors have a worse prognosis than 
adenocarcinoma, while mucinous lesions tend to recur locally. Both of these 
tumors are however more common in the anus. Other varieties are carcinoid 
and Leiomyosarcoma. 
Histological features such as vascular, lymphatic or perineural invasion 
are prognostically unfavorable. By contrast lymphocytic infiltration of the 
tumor and a histolytic reaction in the regional lymph nodes are minor favorable 
prognostic features. 
Identification of surface tumor antigens such as carcinoembryonic 
antigen, oncogene expression and DNA ploidy potential refinement but these 
are not yet in routine use. 
STAGING OF TUMOR 
Several staging methods are in use throughout the world, and each has 
its own strengths and weaknesses. The most commonly used are the Duke’s 
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classification and derivations of it, or the Union international Cancer center 
(UICC) TNM classification. The former has the advantages of great simplicity 
but considerable disadvantages from lack of precision. It does not reflect 
accurately the depth of tumor penetration, the extent of spread outside the 
bowel, the number of lymph nodes affected by tumor or the presence or absence 
of metastasis, all of which have an important bearing upon prognosis. 
Derivations such as the Astler Coller and Australian classifications refine the 
Duke’s staging but do not provide the flexibility of the TNM method, which 
enables useful division into subsets without being unduly complex. It is 
therefore most appropriate that surgeons adopt the TNM classification as a 
suitable international standard. 
Staging gives information about prognosis in general, but particularly 
indicates the probability of occult hepatic metastases which is the major factor 
affecting survival. Patients with Dukes C tumor are more likely to have occult 
hepatic metastasis. Occult hepatic metastases account for the majority of deaths 
from colorectal cancer while only about 20% of patients die from local spread 
of the disease, which is also reflected, in the clinical stage. 
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1. Dukes classified carcinoma of the rectum into three stages. 
Stage A: The growth is limited to the rectal wall  
Stage B: The growth has extended to the extra rectal tissues but no 
metastasis to the regional lymph modes.  
Stage C: There are secondary deposits in the regional lymph nodes [2]. 
ASTLER AND COLLER (1954): 
Has made this classification more accurately in terms of prognosis  
Stage A :  Lesion limited to mucosa. 
Stage B1 :  Lesion penetrating muscularis propria but not through it.  
Stage B2 :  Lesion penetrating muscularis propria and extending into  
     serosa.     
 Negative lymph nodes. 
Stage C1  :  Lesion involves all layers of bowel wall except serosa.    
   Positive lymph nodes 
Stage C2 :  Lesion involves all layers of the bowel walls including  
   serosa. 
   Positive lymph nodes.  
Stage D :  Distant Metastasis 
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TNM Staging (1954) 
 By AJCC(American Joint Commission on Cancer) and 
IUAC(International Union against Cancer) 
T - Staging  
 Tx - primary tumor could not be assessed.  
 T0 - No evidence of primary tumor  
 Tis - Insitu – intraepithelial /invasion of the lamina propria.  
T1 - invades submucosa 
T2 - invades muscularis propria  
T3 - invades through muscularis propria into subserosa / into  
  perirectal tissue  
T4 - invasion of adjacent organs  
N – staging  
 Nx  - Regional lymph nodes could not be assessed.  
 N0 - No nodes  
 N1 - Metastasis in 1-3 pericolic / perirectal lymph nodes  
 N2 - Metastasis in 4/more pericolic / perirectal lymph nodes 
 N3 - Metastasis in lymph nodes along the named vascular trunk  
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TNM STAGING OF CARCINOMA OF RECTUM  
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TNM STAGING OF CARCINOMA OF RECTUM  
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M – staging  
 Mx - Metastasis could not be assessed.  
 M0 - No distant metastasis  
M1 - Distant metastasis  
Comparison of TNM staging, Duke staging and 5 years survival rate 
Stage I T1-2 N0 M0 A 70-95% 
Stage II 
A 
B 
 
T3 N0M0 
T4 N0M0 
 
B 
 
54-65% 
Stage III 
A 
B 
C 
 
T1-2  N1 M0 
T3-4  N1 M0 
T1-4 N2 M0 
 
C 
 
39-60% 
Stage IV T1-4 N0-2 M1 C 0-16% 
 
PROGNOSIS 
Stage remains the most important indicator of prognosis. The prognosis 
of patients with adequately treated Stage IV cancers is little different from that 
of an otherwise healthy population of the same age. 95 to 100% live 5 years or 
more after resection. Patients with cancer spread through the serosa only have a 
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40 to 60% chance of living 5 years, although the prognosis is more favorable if 
the tumor is only just through the serosa and is correspondingly worse if 
adjacent structures are invaded. Lymph node metastasis further adversely 
affects prognosis with only about 30% of patients surviving 5 years. Sub 
classification is useful. The survival curve of patients with colon and rectal 
cancer treated by resection is curvilinear, reaching a nearly flat plateau. 
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EVALUATION OF THE PATIENT 
I. CLINICAL ASSESSMENT  
 Complete history including family history and assessment of risk factors 
are mandatory.  
II. DIGITAL RECTAL EXAMINATION (DRE) 
 To assess size, location of the lesion from the anal verge, type of growth, 
fixity to surrounding structures and sphincter function especially if planned for 
sphincter sparing procedure.  
III. RIGID SIGMOIDOPROCTOSCOPY 
 It is useful for examination of the rectum and sigmoid colon. It is 25 cm 
in length and available in variable diameters. It can be performed without 
anesthesia.  It allows direct visualization of the lesion, site, size of the lesion, 
degree of obstruction and is used to take biopsy, to assess ulceration and degree 
of fixation [1].   
IV. FLEXIBLE SIGMOIDOSCOPY (FSIG) 
Used to take biopsy. Flexible sigmoidoscopy leads to significant 
variability in assessing the level of rectal cancer and level of rectum itself. 
Therefore FSIG is not useful to determine the level of lesion.  
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ENDORECTAL USG SHOWING 
 
Normal rectum  
 
T1 lesion  
 
T3 lesion  
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CT SHOWING  
 
Circumferential wall thickening  of rectum  
 
Liver metastasis  
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V. ENDORECTAL USG  
 Endorectal USG primarily used to evaluate the depth of invasion. It can 
differentiate superficial T1, T2 from deeper T3, T4 lesion. Accuracy is 81 to 
94%. It can detect perirectal lymphnodes also with accuracy rate of 58 to 83% 
and is also useful to detect early recurrence [1].  
VI. CT ABDOMEN AND PELVIS 
 Used for staging colorectal carcinoma. Extravasation of contrast 
indicates perforation (or) anastomotic leakage. It is relatively insensitive for 
detection of the intraluminal lesions [1].  
VII. MRI 
It accurately determines the extent of spread of rectal cancer into mesorectum 
and pelvic wall [1].  
VIII. PET SCAN 
 It is useful in detection of recurrent / metastatic colorectal carcinoma [1].  
IX. DOUBLE CONTRAST BARIUM ENEMA (DCBE) 
 It is highly sensitive for detecting polyps more than 1 cm in diameter 
especially in proximal colon. But its efficacy in screening large population is 
not satisfactory. For screening, it is usually combined with FSIG.  
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Disadvantages of barium enema 
1. Need for bowel preparation  
2. Requirement of colonoscopy if a lesion is detected [1].  
X. CT COLONOGRAPHY / VIRTUAL COLONOSCOPY  
 It was introduced in 1994. It is a high speed helical CT scanner with 3 
dimensional view. Pre procedure bowel preparation is needed. It provides good 
visualization of entire colon including antegrade and retrograde views of 
flexures and haustral folds. If positive for lesion, colonscopy is required.   
XI. FIBEROPTIC FLEXIBLE COLONOSCOPY (FFC) 
 It allows full visualization of entire colon. It detects synchronous lesions. 
It is possible to take biopsy from the lesion.  
XII. OTHER TESTS 
GUAIAC –FOBT 
 2 samples from each of 3 consecutive stools are tested. If any of 6 
samples is positive, FFC is recommended. 
Disadvantages  
Occult blood from any part of the GIT produces positive test. 
Red meat, vitamin C and some fruits also produces false positive results.  
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XIII. FAECAL IMMUNO CHEMICAL TEST (FIT) 
 This test is done by using monoclonal antibody against human 
haemoglobin. It is specific for lower GI bleed because, globin doesn’t survive 
in the upper GI tract. Dietary restrictions are not necessary for this test. Any 
positive test recommends further colonoscopy.  
 
XIV. STOOL DNA SCREENING TEST (SDNA) 
      Done by using polymerase chain reaction on sloughed mucosal cells in 
stool.  
 
XV. TUMOR MARKERS  
Carcinoembryonic antigen (CEA) 
 Baseline level of CEA is measured before surgery and follow up level is 
obtained after surgery. If CEA begins to rise in the postoperative period, it 
suggests possible recurrence. A CEA level of more than 100ng/ml indicates 
metastatic diseases and warrants thorough   investigations.  
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SCREENING GUIDELINES 
 The purpose of the screening is to eradicate potential cancers while they 
are still in the benign stage of adenoma-carcinoma sequence. Screening also 
increases the likelihood of discovering existing cancer.  
 
 
 
 
 
Patients with average risk for colorectal cancers  
 People who are asymptomatic and have no other risk factors.  
 Screening should begins at 50 years and end at 75 years [30]. 
Patients with High risk for colorectal cancers  
 Person with first degree relative affected by colorectal carcinoma.  
Person with family history of FAP and HNPCC,  
Person with personal history of adenomatous  polyps  
Person with personal history of colorectal cancer and IBD [1].  
Screening 
Patients with average 
risk 
Patients with high 
risk 
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Category of 
population Initial age Recommended screening test 
Average risk 
patients 50 years 
Annual FOBT (or) Flexible sigmoidoscopy 
every 5 years (or) annual FOBT and flexible 
sigmoidoscopy every 5 years (or) DCBE 
every 5 years (or) colonoscopy every 10 
years 
Adenomatous 
polyps 50 years 
Colonoscopy in first detection; then 
colonoscopy in 3 years; if no further polyps, 
colonoscopy every 5 years; if polyps present 
- colonoscopy every 3 years. Annual 
colonoscopy for more than 5 adenomatous 
polyps. 
Colorectal cancer At diagnosis 
Pretreatment colonoscopy; then at 12 months 
after curable resection; then colonoscopy 
after 3 years, then colonoscopy every 5 years 
if no new lesions.  
IBD 
At diagnosis, then 
after 8 years of 
pancolitis, 15 yrs 
for L sided colitis 
Colonoscopy with multiple biopsies every 1-
2 years.  
FAP 10-12 years 
Annual flexible sigmoidoscopy and upper GI 
endoscopy every 1-3 years after polyps 
appear.  
Attenuated FAP 20 years 
Annual flexible sigmoidoscopy and upper GI 
endoscopy every 1-3 years after polyps 
appear. 
HNPCC 20-25 years Colonoscopy every 1-2 years, endometrial aspiration biopsy every 1-2 years.  
Familial colorectal 
cancer first degree 
relative 
40 years (or) 10 
years before the 
age of the 
youngest affected 
relative 
Colonoscopy every 5 years. 
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MANAGEMENT OF CARCINOMA RECTUM 
Principle  
 Complete resection of primary tumor, its lymphatic bed and any other 
involved organ apply to surgical resection of rectal carcinoma. But, the 
anatomy of the pelvis and proximity of other structures (ureters, bladder, 
prostate, vagina, sacrum, iliac vessels) make resection more challenging and 
require a different approach than colonic adenocarcinoma and also obtaining 
negative radial margins in rectal cancers are also very difficult.  Hence local 
recurrence is higher than with similar stage colon cancers. Paucity of small 
bowel and other radiosensitive structures in the pelvis makes it easier to treat 
rectal tumor with radiation. Therefore, therapeutic decisions are based upon the 
location, depth of the tumor and its relationship to other structures in the pelvis.  
STAGE SPECIFIC THERAPY  
 Any rectal carcinoma patients should be evaluated by doing endorectal 
USG, MRI pelvis, CT abdomen and pelvis and colonoscopy. By using this, 
staging evaluation can be done.  
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Stage I (T1-T2 N0M0) 
 In high risk patients and patients accepting radical resection, radical 
procedures are done. In low risk patients and those not accepting the radical 
resections, local therapy such as transanal excision, transanal endoscopic 
surgery and endocavitatory irradiation are done. These patients are better 
treated with neo adjuvant or adjuvant chemoradiation [1].  
Stage II (T3-4 N0 M0) 
 For managing stage II rectal carcinoma, there are two schools of thought. 
Advocates suggest that optimized operative technique (TME) will not need any 
adjuvant / neo adjuvant chemoradiation. Opponents suggest that, neo adjuvant / 
adjuvant chemoradiation will reduces local recurrence and prolong the 
survival[1].  
Advantages of neo adjuvant chemoradiation  
- Tumor shrinkage  
- Downstaging the disease by treating locally involved 
lymphnodes 
- Possibility of sphincter sparing procedure  
- Improved resectability.  
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Disadvantages  
- Poor wound healing  
- Pelvic fibrosis  
- Over treatment of early stage tumors  
Post operative chemoradiation  
 It allows accurate pathologic staging of resected tumor and lymph nodes. 
It avoids poor wound healing.  
Stage III (any T, Any N, M0) 
 Neoadjuvant chemoradiation  
 
 Restage the tumor  
 
 If no metastasis  
 
 Radical resection [1].  
Stage IV (Any T, Any N, M1) 
  Survival is limited in patients with distant metastasis. Isolated 
pulmonary/ hepatic metastasis is rare, if present may be resected for cure. Most 
patients require palliative procedures. Radical resection may be required to 
control pain, bleeding but highly morbid procedures such as pelvic exenteration 
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and sacrectomy generally should be avoided. Local therapy using intraluminal 
stents, cautery, endocavitory irradiation / laser ablation may be adequate to 
control bleeding / prevent obstruction [1].  
OPERATIVE PRELIMINARIES  
1. BOWEL PREPARATION  
 The rationale for bowel preparation is that decreasing the bacterial load 
in the colon and rectum, will decrease the incidence of post operative 
infections. The most commonly used regimens include polyethylene glycol 
(PEG) solutions and sodium phosphate solutions. PEG and sodium phosphate is 
equally efficacious in bowel preparation [1].  
Disadvantages of PEG 
1. Patient has to drink large volume  
2. Bloating and nausea. 
Disadvantages of sodium phosphate  
1. Fluid and electrolyte abnormalities.  
 
 
46 
 
II. ANTIBIOTIC PROPHYLAXSIS  
 The addition of oral antibiotics to the preoperative mechanical bowel 
preparation is thought to decrease postoperative infection by further decreasing 
the bacterial load of the colon. A combination of three doses of neomycin ( 1 
gm) and erythromycin (1 gm) is most commonly used. Metronidazole or 
ciprofloxacin may be used instead of erythromycin to avoid GI upset.  A broad 
spectrum parenteral antibiotics should be administered just before the skin 
incision [1].  
III. STOMA PLANNING  
  Preoperative stoma planning includes  
- Counselling  
- Education  
- Stoma siting 
- Evaluation of other medical condition that may impact a 
patient ability to manage a stoma (eyesight, manual 
dexterity)[1].  
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REVIEW OF VARIOUS SURGICAL MODALITIES 
1. LOCAL SURGICAL PROCEDURES  
a. Transanal excision  
b. Transanal endoscopic microsurgery  
c. Electrocautery / endocavitary irradiation  
a. Transanal excision  
 Transanal excision is reserved for early stage cancers in a select group of 
patients. Criteria for Transanal excision  
1. Lesion less than 3 cm in size.  
2. Lesion occupying less than 1/3 of circumference of rectum.  
3. Exophytic / polypoidal growth  
4. Low grade tumors (well differentiated)  
5. Tumors located within 8 cm of anal verge  
6. T1 lesions  
7. T2 in select groups [31,32].  
The lesion is excised fully with 1 cm margin of normal tissue and 
leaving defect closed.  
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Positive resected margin, lymphovascular invasion, lymphnode 
metastasis in post operative histopathological examination mandate further 
radical procedures[32].  
b. Transanal endoscopic microsurgery  
 It is another form of local excision by using special operating 
proctoscope that distends the rectum with, insuffalated Co2 and allows the 
passage of dissecting instruments.  
 This method can be used on lesions located higher in the rectum, even in 
the distal sigmoid colon.  
c. Endocavitary irradiation  
  The selection criteria for this procedure are similar to those for TNA. 
Endocavitary irradiation is delivered by a special proctoscope. A total of 6 
application of high dose (20 Gy to 80 Gy) low voltage irradiation 50 KV is 
given over the course of 6 weeks [32].  
2. ANTERIOR RESECTION  
 It is the resection of rectum from an abdominal approach to the pelvis, 
without need for a perineal / sacral incision.  
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Three types  
a. High anterior resection – Done for upper 1/3rd lesions  
b. Low anterior resection – Done for middle 1/3rd lesions  
c. Extended low anterior resection – Done for lower 1/3rd lesions  
In high and low anterior resection continuity is restored by colorectal 
anastomosis. In extended low anterior resection continuity is restored by 
coloanal anastomosis.  
The coloanal anastomosis is done either by straight tube coloanal 
anastomosis or creation of colonic ‘J’ pouch anal anastomosis.  
The anastomosis is done by either handsewn technique or with stapling 
device.  
The acceptable distal and proximal resected margins for rectal 
cancer[26]. 
Resection margin 
Proximal resection 
margin in cm 
Distal resection margin 
in cm 
Ideal margin 5 cm/more  2 cm/more 
Minimally acceptable margin 5 cm/more 1 cm/more  
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CIRCULAR STAPLING INSTRUMENT  
 
 
 
SCHEMATIC REPRESENTATION OF STAPLING TECHNIQUE  
 
 
 
51 
 
Transmesorectal excision (TME) 
 Transmesorectal excision is a technique that uses sharp dissection along 
the anatomic planes to ensure complete resection of rectal mesentery during 
low and extended low anterior resections. For upper rectal / rectosigmoid 
resection, a partial mesorectal excision of atleast 5 cm. distal to the tumor 
appears adequate. Transmeorectal excision decreases both local recurrence rate 
and improves long term survival rates.  
 Principles of TME should be applied to all radical resection of rectal 
cancer.  
3. ABDOMINO PERINEAL RESECTION   (APR) 
 APR is performed with lower 1/3rd rectal cancers. APR involves removal 
of the entire rectum, the anal canal and anus with construction of permanent 
colostomy from the descending / sigmoid colon.  
 Two team approaches is used. The abdominal team mobilizes the colon 
and rectum, transect the colon proximally and creates an end sigmoid 
colostomy. The perineal team begins by closing the anus by purse string 
sutures. The perineal team is designed to excise the anal canal with wide 
circumferential margin. The perineal wound is closed after keeping a closed 
suction drain.  
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LOW ANTERIOR RESECTION - SPECIMEN   
 
 
 
APR - SPECIMEN   
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4. LAPROSCOPIC ASSISTED APR          
 Mobilisation of sigmoid colon, rectum is done through laproscopy and 
perineal resection is done by usual open method.  
5. POSTERIOR RESECTION  
 a. Trans sacral  
 b. Trans sphincteric  
Trans sacral – Kraske’s 
 For middle one third rectal lesions. Coccyx and lower 2 segments of 
sacrum excised. There will be increased risk of fecal fistula.  
Trans sphincteric – York Mason’s  
 No sacrectomy needed. Sphincteric complex carefully delineated, 
divided and re approximated. Decreased risk of fecal fistula, but increased risk 
of incontinence present.     
RADIATION THERAPY  
 A multidisciplinary approach that includes, colorectal surgery, medical 
oncology and radiation oncology is required for optimal treatment of rectal 
carcinoma. Although radical resection of rectum is the main stay of therapy, 
54 
 
surgery alone has high recurrence rate (30-50%). So, adjuvant radiation therapy 
is advocated.  
Radiation therapy can be delivered  
 Preoperatively / neo adjuvant  
 Intra operatively  
 Post operatively  
NEO ADJUVANT /PREOPERATIVE RADIATION THERAPY  
Advantages  
- Tumor shrinkage  
- Down staging of the disease 
- Improved resectability  
- Possible of sphincter sparing procedures  
- Minimizes the radiation exposure to small intestines due to 
pelvic displacement and adhesions following surgery.  
- Radiation therapy is also effective, if given preoperatively 
because cells are well oxygenated before surgery. Post 
operatively cells are relatively hypoxic and resistant to 
radiotherapy [7, 28].  
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Disadvantages  
- Poor wound healing  
- Anastomotic leak  
- Delay in starting definitive treatment 
- Loss of accurate pathological staging  
- Possibility of over treatment of early stage I and II 
carcinomas.  
INTRAOPERATIVE RADIATION THERAPY  
 It is recommended in patients with large bulky fixed, unresectable 
tumors. It requires specialized, expensive operative room with equipment, 
limiting its use.  
POST OPERATIVE ADJUVANT RADIATION THERAPY  
Advantages  
- Immediate definitive resection  
- Accurate pathological staging can be done.  
- No preoperative radiation therapy induced morbidity.  
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Disadvantages  
- Delay in adjuvant radiation therapy if postoperative 
complications ensue.  
- No effect on tumor cell spread at the time of surgery.  
- Decreased effect of radiation in tissues with surgically induced 
hypoxia.  
CHEMOTHERAPY  
 Chemotherapy options for colon and rectal cancers have greatly 
expanded in recent years. The most useful drug for colorectal carcinoma is 
5FU. 5FU is a fluorinated pyrimidine, which blocks the formation of thymidilic 
acid and DNA synthesis. It offers good radiosensitization without severe side 
effects. 5FU has been used in conjunction with radiation (combined modality) 
therapy before surgery (neo adjuvant) as well as after surgery.  
 Stage I and II rectal cancers with radical surgery do not require 
adjuvant therapy. High risk patients including those with poorly differentiated 
tumor histology and those with lymphovascular invasion should be considered 
for adjuvant chemoradiation.  
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Stage III and IV (Locally advanced tumors) All patients should 
receive neo adjuvant chemoradiation which improves local control, distant 
spread and survival.  
Regimens used in stage III and IV disease include: 
FOLFOX (Folinic acid, 5 FU, Oxaliplatin) 
FOLFIRI (Folinic acid, 5FU, Irinotecan)  
In recent randomized phase III studies, panitumumab, a monoclonal 
antibody for EGFR, combined with FOLFOX or FOLFIRI significantly 
improved progression free survival when compared to FOLFOX or FOLFIRI 
alone in patients with metastatic colorectal cancer and wild type Kras 
status[33,34].  
COMMON REGIMENS  
FOLFOX (every 2 wks) 
 Oxaliplatin 85 mg/m2 Day 1  
 Leucovarin 200mg/m2 Day 1 
 5FU 400 mg/m2 IV Bolus Day 1 and 2 
 5FU 600mg/m2 IV Infusion Day 1 and 2 Over 22 hours.   
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FOLFOX 4 (every 2 wks, 4 cycles) 
 Oxaliplatin 85 mg/m2 Day 1  
 Leucovarin 200mg/m2 Day 1 
 5FU 400 mg/m2 IV Bolus Day 1 and 2 
 5FU 2400mg/m2 IV Infusion Day 1 (46 hours) 
FOLFIRI (every 2 wks) 
Irinotecan 165 mg/m2 Day 1  
 Leucovarin 200mg/m2 Day 1 
 5FU 400 mg/m2 IV Bolus Day 1 and 2 
 5FU 600mg/m2 IV Infusion Day 1 & 2 (over 22 hours) 
FOLFOXIRI (every 2 wks) 
Irinotecan 180 mg/m2 Day 1  
 Oxaliplatin 85 mg/m2 Day 1  
Leucovarin 200mg/m2 Day 1 
 5FU 3200mg/m2 IV Infusion Day 1 (48 hours) 
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MANAGEMENT OF RECURRENT AND METASTATIC 
CARCINOMA  
Surveillance should be early and most intensive, because recurrent 
disease develops within the first 2 years after primary resection in about 80% of 
patients. 
LOCAL RECURRENCE: 
Recurrent carcinoma may present as a localized tumor at the anastomosis 
or more commonly as recurrent disease in the bed of the primary carcinoma 
growing into the. anastomotic area. The disease may be extensive and may 
involve regional lymph nodes. 
Surgery is the only hope for cure in these patients but frequently the 
extent and dissemination of the disease make complete excision impossible. In 
symptomatic patients, however maximal palliation can be accomplished by 
alternative surgical treatments such as resection, fecal diversion or a bypass 
procedure. Local palliation may be accomplished by transanal laser surgery or 
fulguration in patients with disseminated disease or in poor medical condition. 
More extensive operations including sacral resection or pelvic exenteration are 
reserved for patients with isolated recurrent disease who are in excellent 
medical condition. 
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LIVER METASTASIS: 
Colorectal carcinoma will metastasize to the liver in about 35% of 
patients. Half of these patients will have liver metastases at the time of primary 
resection of the colon. 
At present hepatic resection is the only curative treatment available for 
these patients. The median survival from the time of diagnosis of metastatic 
liver disease is about 4 to 12 months for unselected groups whereas 45% of 
patients with a solitary metastatic lesion may be alive at 2 years and 12% may 
be alive at 3 years. In the absence of resection however survival longer than      
5 years is almost never possible.  
The Grade of the tumor may have some influence on the survival of 
patients with untreated liver metastases. In the series by (Goslin et al) the 
median survival time for patients with well, moderately well and poorly 
differentiated tumor was 30, 16 and 6 months respectively [35]. However the 
relation between the histological findings and the extent of involvement of the 
liver was not reported. 
BLOOD TRANSFUSION: 
Blood transfusion has been alleged to affect survival after resection of 
primary colorectal carcinoma. Similarly perioperative blood transfusion has 
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been found to be an independent prognostic factor adversely affecting survival 
after resection of liver metastases. Specifically, for each additional unit of 
blood, death increased by 5% and 7% respectively. Further studies are directed 
toward decreasing blood loss during hepatic resection to minimize the need for 
blood transfusions. 
At laparotomy for resection of colorectal carcinoma 10% to 26% of 
patients will have synchronous liver metastases.  Usually, simultaneous liver 
resection has been performed with good results however  is safe when patients 
with liver as a solitary metastastic lesion that can be removed by limited 
resection minimal blood loss or contamination in an uncomplicated status that 
would permit both procedures and a surgeon who is comfortable in proceeding 
with the resection. No survival advantages exist performing simultaneous 
versus delayed resection of the liver. 
UNRESECTABLE METASTASIS: 
Liver transplantation for patients with unresectable hepatic disease has 
been reported in Europe. Because of the shortage of donor organs and the lack 
of long term follow-up studies transplantation is not likely to be a feasible 
alternative for the treatment of patients with metastatic disease. 
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Alternative methods of treatment including the use of monoclonal 
antibodies and hepatic cryosurgery are under investigation may prove to be of 
considerable benefit in the future. 
PULMONARY METASTASIS: 
It is estimated that pulmonary metastases will develop in about 10% of 
patients with colorectal carcinoma at some time in the course of the disease. By 
that time in most patients disease will already have spread to other organs. Only 
10% of these patients will actually have a solitary pulmonary metastatic lesion. 
The only hope of cure for patients with pulmonary metastases from 
colorectal carcinoma is resection. In a collective review by Brister et al, the 
survival rate of 335 patients in 12 series who underwent resection of pulmonary 
metastases form colorectal carcinoma was 70% at 2 years and 30% at                 
5 years[36]. Clearly resection should be undertaken whenever a recurrent lesion 
limited to the lung is technically resectable. 
BRAIN METASTASIS: 
Carcinoma metastatic to the brain from a colorectal primary site is 
uncommon and is usually associated with disease elsewhere particularly in the 
lung. Metastatic carcinoma of the brain is usually diagnosed because of the 
presence of neurologic symptoms rather than during screening. Radiation 
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provides the best palliation without increased morbidity. At the same time, in 
the rare situation of a patient whose metastatic lesion in the brain is the only site 
of recurrence craniotomy may prolong the survival. 
OSSEOUS METASTASIS: 
The incidence of bone metastasis among patients with disseminated 
colorectal carcinoma varies among different series. Osseous metastases which 
are uncommon may be the source of considerable pain. The diagnosis is usually 
achieved with bone scans. Palliative treatment by means of radiation is usually 
effective. 
OVARIAN METASTASIS: 
The ovary is the site of metastatic diseases in 3% to 8% of women with 
colorectal carcinoma. Metachronous ovarian metastases cause considerable 
morbidity and overall are associated with poor survival. Patients with ovarian 
metastases of colorectal origin should undergo aggressive surgical therapy. 
Bilateral oophorectomy should be performed even in patients with unilateral 
ovarian involvement. Some authors recommended prophylactic bilateral 
oopherectomy as part of the initial surgical treatment for colorectal carcinoma 
in premenopausal women with advanced stages of disease and in all 
postmenopausal women. 
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MATERIALS AND METHODS 
 This study has been conducted in the Department of Surgery, Govt. 
Rajaji Hospital, Madurai during 2009-2011. Patients admitted in general 
surgery units, surgical gastroenterology and surgical oncology department were 
selected. All patients were subjected to detailed history, thorough clinical 
examination of the abdomen, digital rectal examination, proctoscopy and 
biopsy was taken for histopathological examination.  
 All these patient had base line biochemical investigations done including 
blood-Hb%, TC, DC, Blood Sugar, Blood Urea, Serum Creatinine, Urine-sugar, 
albumin, microscopy, liver function test, ultrasonography, double contrast 
barium enema when warranted, CT abdomen and pelvis plain and contrast, 
Magnetic Resonance Imaging when feasible.  
 All patients were counseled with regards to treatment side effects, 
possible outcome with and without the preoperative chemoradiotherapy, the 
side effects during the course. The patients were counseled with regard to 
colostomy. During the counseling session a previous ostomate was included. 
  Patients were staged according to the TNM classification system 
using clinical and radiological data. Patients those who were included in neo 
adjuvant chemoradiation were investigated thoroughly and underwent 
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radiotherapy 45-60 Gy in 150-200 cGy fractions for 5 days a week and 
concurrent 5-FU 10mg/kg and leucovorin 30mg infusion every 21 days for 6 
cycles was given. They were again restaged clinically and radiologically. 
 Preoperative bowel preparation with polyethylene glycol and intravenous 
antibiotics was given to all patients. Postoperatively patients were followed up. 
Postoperative adjuvant chemotherapy was given to most of the patients with 5-
FU 500mg given for the first 3 days of every fortnight for 6 months along with 
leucovorin. Majority of the patients were regularly followed up for one year. 
All these data were recorded in a proforma.  
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RESULTS 
TABLE 1: Age distribution  
Age in years Male Female Total Percentage 
20-30  2 1 3 6% 
31- 40 5 5 10 20% 
41-50 8 4 12 24% 
51-60 10 4 14 28% 
61-70 8 2 10 20% 
71-80  1 0 1 2% 
Out of 50 cases, in our study most number of the carcinoma rectum cases 
occurs in 5th decade (28%). Incidence started to increase from 3rd decade 
reaches peak at 5thdecade, then again fall after 6th decade. Usually the incidence 
is rising steadily after the age of 50 and more than 90% of cases diagnosed are 
in people older than 50 years of age [1]. But in our study equal distribution of 
cases observed before and after 50 years of age and in cidence started to rise 
after 30 years of age.   Among males maximum number of cases occurs 
between 4th and 6th decade, and in females between 3rd and 5th decade i.e. in 
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females carcinoma rectum occurs one decade earlier than males in our study. 
Mean age of incidence is 50.4 in our study. 
 
Fig1. Age distribution in Males & Females  
 
Fig 2.  Age distribution in Males & Females 
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Sex distribution  
Total number of cases in our study  - 50 
Total number of male patients   - 34(68%) 
Total number of female patients   - 16(32%) 
Male to female ratio    - 2:1  
 
 
 
 
Fig 3. Sex distribution  
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TABLE 2: Symptoms  
Symptoms  No. of patients  Percentage  
Bleeding per rectum 38/50 76 
Constipation  29/50 58 
Pain  12/50 24 
Tenesmus 14/50 28 
Diarrhoea  6/50 12 
Acute intestinal obstruction 8/50 16 
 
 
Fig 4. Symptoms 
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TABLE 3: Site of lesion  
Site of lesion  No. of patients  Percentage  
Upper 1/3rd   6 12 
Middle 1/3rd  17 34 
Lower 1/3rd 27 54 
 
 
Fig 5. Site of lesion  
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TABLE 4: Stage of the disease 
Stage No. of patients  Percentage  
Stage I & II 18 36 
Stage III 24 48 
Stage IV 4 8 
Staging not done  4 8 
 
Two cases that presented as acute intestinal obstruction did not turn up 
after loop colostomy. One case expired during postoperative period following 
loop colostomy. Another case was not affordable for doing investigations.    
 
Fig 6. Stage of the disease   
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 TABLE 5: Adjacent organ involvement  
Adjacent organ involvement No. of patients Percentage 
Bladder infiltration  2 4 
Sacral infiltration  1 2 
Vaginal infiltration  1 2 
Prostate & bladder 
infiltration 
1 2 
 
 
Fig 7.  Adjacent organ involvement  
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TABLE 6: Distant metastasis  
Distant metastasis  No. of patients  
Liver metastasis alone 3 
Liver metastasis and ascites  1 
 
TABLE 7: Surgeries  
Surgeries  No. of patients  Percentage  
Abdomino Perineal 
Resection 
20/45 44 
Lap. APR  10/45 22 
AR 7/45 16 
Loop colostomy 8/45 18 
Inoperable  5  
 
 
Fig 8.  Surgeries    
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TABLE 8: Postoperative morbidity  
Postoperative morbidity  No. of patients  Percentage  
Perineal wound infection  5/30 16.6 
Perineal wound gaping 1/30 3.3 
Abdominal wall infection 1/45 2.2 
Retention of urine  2/45 4.4 
Impotence 1/45 2.2 
 
 
Fig 9.  Postoperative morbidity 
 
75 
 
 
TABLE 9: Postoperative mortality  
Postoperative mortality 
No. of patients  Percentage  
1/45 2.2 
 
Neo Adjuvant chemoradiation 
Neo adjuvant chemoradiation therapy was given for five stage III 
diseases. Among the 5 cases, anterior resection was done for three cases and 
APR was done for two cases. Out of the 5 patients, one patient developed 
perineal wound gaping and two patients developed perineal wound infection. 
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DISCUSSION 
 Rectal malignancy is one among the common malignancies presenting at 
Government Rajaji Hospital, Madurai.  
Age Distribution 
 In our study most number of carcinoma rectum cases occurs in 5th 
decade (28%). Incidence started to increase from 3rd decade, reaches peak at 5th 
decade, then again fall after 6th decade. Usually the incidence is rising steadily 
after the age of 50 and more than 90% of cases diagnosed are in people older 
than 50 years of age [1]. But in our study equal distribution of cases observed 
before and after 50 years of age and incidence started to rise after 30 years of 
age. Among males maximum number of cases occurs between 4th and 6th 
decade, and in females between 3rd and 5th decade- i.e. in females carcinoma 
rectum occurs one decade earlier than males in our study. The mean age of 
incidence in our study is 50.4. Deo S Kumar et al reported   the mean age of 
incidence as 45.4 years in their study [17]. The incidence of rectal cancer in 
young patients i.e. between 20-30 years is usually rare. In our study the 
incidence of carcinoma rectum in patients aged between 20-30 years is 6% 
which coincided with an incidence of 5% in Ashutosh Mukerji et al study [18]. 
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Sex Distribution 
In our study, out of 50 patients, 34 patients (68%) were male and 16 
patients (32%) were female with male predominance with the ratio of 2:1. But 
Stein W et al reported the incidence of colorectal cancers in females as 53% [13]. 
This huge variation in sex distribution pattern may be due to geographical 
variation and inclusion of other colonic malignancies in their study.  
Symptoms  
 The most predominant symptom in our study was bleeding per rectum 
which constitutes 76%. The next predominant symptom was constipation in 
58% of patients. Pain was present in 24% of cases. This pattern of 
symptomatology coincided with Kyle SM et al study [14]. In our study, 16% of 
patients presented with acute intestinal obstruction in contrast with Kyle SM et  
al study which showed a 23% occurrence[14]. The median duration of symptoms 
prior to the diagnosis was 70 days in our study. Kyle SM et al reported the same 
as 90 days [14]. There is no correlation existing between tumor stage and 
duration of symptoms in our study.  
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Site of involvement  
 Commonest site of involvement was lower 1/3rd of rectum of about 54%. 
Involvement in middle 1/3rd of rectum was 34%. Involvement in the upper 1/3rd 
was the least with 12%. Deo S Kumar et al also reported a similar distribution 
of site of involvement [17].  
Staging of the disease  
 The staging of the disease was done by using ultrasound abdomen pelvis, 
CT abdomen and pelvis and MRI if feasible. In our study, most of the patients 
were in stage III (T1-4 N1-3 M0) which constitutes 48%. 36% of patients were 
in stage I and stage II. 8% of patients came under stage IV because of their 
metastatic involvement in liver. In our study staging could not be done in 4 
cases. Because two cases presented as acute intestinal obstruction did not turn 
up after loop colostomy. One case expired during post operative period 
following loop colostomy in the 4th post operative day and another case could 
not afford investigations. Stein W et al reported Stage I and II (Duke’s A &B) 
in 52% of cases, Stage III and IV (Duke’s C & D) in 48% of cases [13]. In our 
study, patients under stage I and II was 36% as against 52% in their study. 
Patients under Stage III and IV were 56% as against 48%. This difference may 
be due to lack of screening program and lack of awareness of disease symptoms 
among patients.   
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Surgery  
 20 patients underwent abdomino perineal resection (44%), 10 patients 
underwent laproscopic assisted abdomino perineal resection (22%), 7 patients 
were underwent anterior resection (16%). 
 8 patients were presented with acute intestinal obstruction and they 
underwent emergency loop colostomy.  
 5 patients were inoperable for whom palliative chemotherapy / 
radiotherapy was given. Deo S Kumar et al reported 75% of the patients 
underwent curative resection with abdominoperineal resection in contrast with 
66% in our study [17]. They did not mention about sphincter preserving 
surgeries. We did anterior resection in 16% of patients. Totally 82% of patients 
with carcinoma rectum underwent curative resection in our study. 
Morbidity  
 The most common post operative morbidity in our study was perineal 
wound infection in 16.6% of patients. Perineal wound gaping was present in 
3.3% of cases. Abdominal wound infection was present in 2.2% cases. Both 
perineal wound infection and abdominal wound infection was treated with 
appropriate antibiotics and dressing after obtaining pus culture and sensitivity. 
Perineal wound gaping healed by proper wound care. Retention of urine was 
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present in 2 patients and impotence was reported 1 patient. The overall 
morbidity rate was 28.7%. Both Deo S Kumar et al and Bogdan C Paun et al 
reported the overall morbidity rate in their studies as 23% and 20% 
respectively[17,19]. The slight increase in morbidity rate in our study emphasized 
to focus on quality improvement in pre-, intra-, and post operative efforts.   
Mortality 
 2 cases expired in our study. One case which presented with liver 
metastases with liver failure expired before starting any palliative therapy.  
Another patient was admitted with acute intestinal obstruction with perforation. 
Emergency loop colostomy was done. He expired on IVth postoperative day due 
to multi organ failure and septicemia. Both Deo S Kumar et al and Bogdan C 
Paun et al reported the post operative mortality in their study as 2% which 
coincides with our study (2.2%) [17,19].   
Neo adjuvant chemoradiation  
 In our study, neo adjuvant chemoradiation was given in 5 patients. All 
patients were admitted in stage III. After administration of neo adjuvant 
chemoradiation, among 5 patients, anterior resection was done in 3 
patients(60%) and APR was done in 2 patients(40%). This leads to the 
conclusion that the preoperative neo adjuvant chemoradiaton is important in 
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improving respectability and sphincter preservation rate, but there is increased 
post operative morbidity like perineal wound gaping and perineal wound 
infection. Janjan NA et al reported almost the same 59% of sphincter preserving 
procedures and 41% of abdominoperinal resection in their study after 
neoadjuvant chemoradiation [16].  
Follow up  
 During follow up period, 1 patient developed pelvic recurrence and 1 
patient developed liver secondaries. Both patients were Stage III patients and 
neo adjuvant chemoradiation was not available for both of them. This shows the 
role of neoadjuvant chemoradiation in reducing the incidence of local 
recurrence and distant metastasis. In all sphincter sparing surgery done patients, 
follow up sigmoidoscopy was done and found to be normal.   
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CONCLUSION                                                           
- In our study, the peak incidence was in the 5th decade. The incidence 
started to rise after 30 years of age and equal distribution of cases 
observed before and after 50 years of age with male: female ratio 2:1. In       
females, carcinoma rectum occurs one decade earlier than males.    
- Bleeding per rectum was the most common presentation and lower 1/3rd 
of rectum was the commonest site of involvement. 
- Most cases presented with stage III which emphasizes the importance of 
the role of screening program and to create awareness of disease among 
general population. 
- Abdomino perineal resection was the most frequently done surgery in 
our study.  Perineal wound infection was the commonest post operative 
morbidity which emphasizes the need for improvement in pre-,intra-
,post-,operative care. 
- Neoadjuvant chemoradiation improves resectabilty and sphincter sparing 
rate but however there is an increased incidence of perineal wound 
infection and wound gaping. 
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PROFORMA 
Name :    Age/Sex:    IP No: 
D.O.A.    D.O.S.: 
Presenting complaint Bleeding  
    Constipation  
    Pain  
    Tenesmus 
    Diarrhoea 
    Obstruction  
Duration of symptoms (in days):                                        
General condition   Pulse  
    BP 
Digital Rectal Examination  
Proctoscopy 
Colonoscopy / Sigmoidoscopy 
USG Abdomen & Pelvis  
CT Abdomen & Pelvis  
MRI 
CRT Regimen & Date of staring therapy  
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 Lab Investigations  
Hb%  TC  DC 
Blood grouping & Rh typing     CXR: 
Urine         ECG: 
- Albumin    
- Sugar  
- Deposits       Biopsy report : 
Blood  
- Urea 
- Sugar  
- S.creatinine 
LFT 
 
Stool for occult blood  
 
Surgical procedure  
Preoperative findings: 
 
Postoperative follow up: 
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ABBREVIATIONS 
IMA    - Inferior Mesenteric Artery  
APC    - Adenomatous Polyposis Colon 
HNPCC   - Hereditary Nonpolyposis Colonic Cancer 
IBD    - Inflammatory Bowel Disease  
AJCC    - American Joint Commission on Cancer 
IUAC    - International Union Against Cancer  
DRE    - Digital Rectal Examination  
FSIG    - Flexible Sigmoidoscopy 
DCBE    - Double Contrast Barium Enema  
FFC    - Fiberoptic Flexible colonoscopy  
FOBT    - Faecal Occult Blood Test  
CEA    - Carcino Embryonic Antigen  
TAE    - Trans Anal Excision  
TEM    - Trans Anal Endoscopic micro Surgery  
AR    - Anterior Resection  
APR    - AbdominoPerineal Resection  
LAAPR   - Laparoscopic Assisted AbdominoPerineal 
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                                                             Resection 
CRT    - Chemoradiation Therapy  
L 1/3    - Lower 1/3rd 
M 1/3    - Middle 1/3rd 
U 1/3    - Upper 1/3rd  
P.W.I    - Perineal Wound Infection  
P.W.G.   - Perineal Wound Gap 
A.W.I.    - Abdominal Wound Infection  
Mets     - Metastases  
LM                   - Liver Metastasis 
A                     - Ascites 
LC    - Loop Colostomy 
RU    - Retention of urine 
IMP    - Impotence 
PR    - Pelvic Recurrence 
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P
1 33 M 043158 + + ‐ ‐ ‐ ‐ 75 L 1/3  + ‐ ‐ ‐ ‐ APR PWG ‐ + ‐ ‐ ‐
2 66 F 047144 + ‐ ‐ ‐ ‐ ‐ 90 M 1/3 ‐ ‐ + LM Bladder invasion ‐ ‐ ‐ + + ‐ ‐
3 60 M 049149 + ‐ + ‐ ‐ ‐ 80 U 1/3 + ‐ ‐ ‐ ‐ AR ‐ ‐ + ‐ ‐ ‐
4 65 M 050702 ‐ + ‐ ‐ ‐ ‐ 60 M 1/3 ‐ + ‐ ‐ ‐ AR ‐ ‐ + ‐ + ‐
5 55 M 051016 + + ‐ + ‐ + 45 L  1/3 ‐ ‐ ‐ ‐ ‐ LC  PATIENT NOT TURN UP ‐
6 65 M 051910 + + + ‐ ‐ + 30 L 1/3 ‐ ‐ + LM ‐ LC ‐ ‐ + ‐ ‐ ‐
7 34 M 059149 + ‐ ‐ ‐ ‐ ‐ 65 L 1/3 ‐ + ‐ ‐ ‐ AR ‐ ‐ + ‐ + ‐
8 31 M 059250 + ‐ + ‐ ‐ + 90 M 1/3 ‐ + ‐ ‐ Bladder invasion LC ‐ ‐ + ‐ ‐ ‐
9 55 M 059257 + + ‐ + ‐ ‐ 80 L  1/3 ‐ + ‐ ‐ ‐ LAAPR ‐ ‐ + ‐ ‐ ‐
10 45 M 062586 ‐ ‐ + + ‐ + 75 L  1/3 ‐ ‐ ‐ ‐ ‐ LC PATIENT NOT TURN UP ‐
11 60 M 064431 + ‐ ‐ ‐ + ‐ 60 U  1/3 + ‐ ‐ ‐ ‐ AR ‐ ‐ + ‐ ‐ ‐
12 41 F 064829 ‐ + ‐ ‐ ‐ ‐ 90 L 1/3 ‐ + ‐ ‐ ‐ APR PWI ‐ + ‐ + ‐
13 48 M 065894 + + ‐ ‐ ‐ ‐ 90 M 1/3 + ‐ ‐ ‐ ‐ APR ‐ + ‐ ‐ ‐
14 38 M 065919 ‐ ‐ + ‐ ‐ ‐ 90 M  1/3 + ‐ ‐ ‐ ‐ APR PWI ‐ + ‐ ‐ ‐
15 60 F 075117 + + ‐ ‐ ‐ ‐ 80 L  1/3 ‐ + ‐ ‐ ‐ APR ‐ ‐ + ‐ ‐ PR 
16 73 M 086628 + ‐ ‐ ‐ ‐ + 75 U  1/3 ‐ ‐ ‐ ‐ ‐ LC ‐ + ‐ ‐ ‐ ‐
17 40 F 093790 + + + ‐ ‐ ‐ 90 L  1/3 ‐ + ‐ ‐ Sacral invasion ‐ ‐ ‐ + + ‐ ‐
18 48 M 0106892 + + ‐ + ‐ ‐ 60 M 1/3 ‐ + ‐ ‐ ‐ APR ‐ ‐ + ‐ ‐ ‐
19 55 M 000812 + + ‐ ‐ ‐ ‐ 30 M  1/3 + ‐ ‐ ‐ ‐ LAAPR ‐ ‐ + ‐ ‐ ‐
20 70 M 003738 + ‐ ‐ ‐ + ‐ 45 M  1/3 ‐ + ‐ ‐ ‐ APR ‐ ‐ + ‐ ‐ ‐
21 65 M 003809 ‐ + ‐ ‐ ‐ + 75 U  1/3 ‐ ‐ ‐ ‐ ‐ LC ‐ ‐ + ‐ ‐ ‐
22 20 M 004421` + ‐ ‐ + ‐ ‐ 80 M  1/3 ‐ + ‐ ‐ ‐ AR RU ‐ + ‐ ‐ ‐
23 50 M 006795 + + ‐ + ‐ ‐ 30 L 1/3 ‐ + ‐ ‐ ‐ AR ‐ ‐ + ‐ + ‐
24 55 F 007070 + + ‐ ‐ ‐ ‐ 90 M 1/3 + ‐ ‐ ‐ ‐ APR PWI ‐ + ‐ ‐ ‐
25 60 F 011383 + + + ‐ ‐ ‐ 90 L  1/3 ‐ + ‐ ‐ Vaginal invasion ‐ ‐ ‐ + + ‐ ‐
26 65 M 011423 + ‐ ‐ ‐ ‐ ‐ 70 L  1/3 ‐ + ‐ ‐ ‐ LAAPR ‐ + ‐ ‐ LM
27 50 F 014857 ‐ + ‐ ‐ ‐ ‐ 85 L  1/3 ‐ ‐ + LM+A ‐ ‐ ‐ ‐ + ‐ ‐ ‐
28 57 M 015721 ‐ + ‐ ‐ ‐ ‐ 90 U  1/3 ‐ + ‐ ‐ ‐ AR ‐ ‐ + ‐ ‐ ‐
29 62 M 028449 ‐ + ‐ + ‐ ‐ 60 L  1/3 ‐ + ‐ ‐ ‐ LAAPR ‐ ‐ + ‐ ‐ ‐
30 67 F 037537 + ‐ ‐ ‐ + ‐ 30 U  1/3 + ‐ ‐ ‐ ‐ AR ‐ ‐ + ‐ ‐ ‐
31 40 F 038642 + + + ‐ ‐ ‐ 80 L  1/3 ‐ + ‐ ‐ Vaginal invasion ‐ ‐ ‐ + + ‐ ‐
32 51 M 045813 + ‐ ‐ + ‐ ‐ 70 L  1/3 ‐ + ‐ ‐ ‐ APR ‐ ‐ + ‐ ‐ ‐
MASTER CHART 
33 40 F 046474 ‐ + ‐ + ‐ ‐ 30 L  1/3 + ‐ ‐ ‐ ‐ APR RU ‐ + ‐ ‐ ‐
34 44 F 048333 + ‐ ‐ ‐ ‐ ‐ 60 M  1/3 + ‐ ‐ ‐ ‐ APR ‐ ‐ + ‐ ‐ ‐
35 34 M 048762 + ‐ ‐ ‐ ‐ ‐ 60 L  1/3 + ‐ ‐ ‐ ‐ LAAPR ‐ ‐ + ‐ ‐ ‐
36 25 M 052095 + + + ‐ ‐ + 90 M  1/3 ‐ + ‐ ‐ Prostate invasion +BI LC AWI ‐ + + ‐ ‐
37 42 M 059149 + ‐ ‐ + ‐ ‐ 90 L  1/3 + ‐ ‐ ‐ ‐ APR IMP ‐ + ‐ ‐ ‐
38 60 M 061909 + + ‐ ‐ ‐ ‐ 75 L  1/3 ‐ + ‐ ‐ ‐ APR ‐ ‐ + ‐ ‐ ‐
39 45 M 064998 + ‐ ‐ + ‐ ‐ 60 M  1/3 ‐ + ‐ ‐ ‐ APR PWI ‐ + ‐ + ‐
40 40 F 070671 ‐ + ‐ ‐ ‐ ‐ 70 L  1/3 + ‐ ‐ ‐ ‐ APR ‐ ‐ + ‐ ‐ ‐
41 69 M 091189 + ‐ + ‐ ‐ + 60 L  1/3 ‐ ‐ + LM ‐ LC ‐ + ‐ ‐ ‐ ‐
42 58 M 002757 + ‐ ‐ ‐ + ‐ 90 M  1/3 ‐ + ‐ ‐ ‐ APR ‐ ‐ + ‐ ‐ ‐
43 48 M 008841 + + ‐ ‐ ‐ ‐ 90 M 1/3 ‐ + ‐ ‐ ‐ LAAPR ‐ ‐ + ‐ ‐ ‐
44 70 M 027342 + ‐ + ‐ ‐ ‐ 30 L  1/3 + ‐ ‐ ‐ ‐ LAAPR ‐ ‐ + ‐ ‐ ‐
45 24 F 016406 + + ‐ ‐ ‐ ‐ 45 L  1/3 + ‐ ‐ ‐ ‐ APR ‐ ‐ + ‐ ‐ ‐
46 55 F 047210 + + ‐ ‐ ‐ ‐ 90 L  1/3 ‐ + ‐ ‐ ‐ APR ‐ ‐ + ‐ ‐ ‐
47 40 F 058254 + ‐ + + ‐ ‐ 80 L  1/3 + ‐ ‐ ‐ ‐ APR PWI ‐ + ‐ ‐ ‐
48 58 M 042486 ‐ + ‐ + + ‐ 90 L  1/3 + ‐ ‐ ‐ ‐ LAAPR ‐ ‐ + ‐ ‐ ‐
49 50 M 089308 ‐ + ‐ ‐ + ‐ 45 M  1/3 + ‐ ‐ ‐ ‐ LAAPR ‐ ‐ + ‐ ‐ ‐
50 41 F  083745 + + ‐ + ‐ ‐ 90 M  1/3 ‐ + ‐ ‐ ‐ LAAPR ‐ ‐ + ‐ ‐ ‐
LM‐ Liver Metastasis    A‐Ascites    APR‐ Abdomino Perineal Resection      AR ‐ Anterior resection    LC ‐ Loop Colostomy    PR ‐ Pelvic recurrence
LAAPR ‐ Laproscopic assisted Abdomino Perineal Resection   PWG ‐ Perineal Wound Gap   PWI ‐ Perineal Wound Infection    AWI ‐ Abdominal Wall Infection
RU ‐ Retension of Urine     IMP ‐ Impotence
